CepTor Corporation Submits Investigational New Drug Application (IND) To Initiate Clinical Trials With Myodur (C-101) In Duchenne Muscular Dystrophy (DMD) Patients

HUNT VALLEY, Md.--(BUSINESS WIRE)--Jan. 17, 2006--CepTor Corporation (OTC BB:CEPO), a development-stage biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, announced that on January 12, 2006 it submitted an IND to the Food and Drug Administration (FDA) to gain permission to begin human trials in DMD patients with Myodur, the Company's muscle cell-targeted calpain inhibitor compound. It is a regulatory requirement that the FDA approve an IND for any drug or biologic before human investigation is allowed to commence. The IND approval process normally takes about 30 days. That time period may be extended if the FDA has questions regarding the IND submission or requires additional data. The Company hopes to initiate a phase I/II clinical trial the first part of April 2006.
MORE ON THIS TOPIC